Predict your next investment

Venture Capital
revelation-partners.com

See what CB Insights has to offer

Investments

22

Portfolio Exits

2

Funds

4

About Revelation Partners

Revelation Partners invests across healthcare sectors with a focus on commercial companies with proven business models or companies with novel technologies that have clear clinical and regulatory pathways. It actively invests in the following healthcare verticals-medical-devices, biopharmaceuticals, healthcare IT, and healthcare services.

Revelation Partners Headquarter Location

255 California Street 12th Floor

San Francisco, California, 94111,

United States

415-905-7226

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Revelation Partners News

Dren Bio Announces $65 Million Series B Financing to Advance its Lead Asset into the Clinic and to Accelerate Development of New...

Jun 17, 2022

– Momentum continues to build for Dren Bio after successfully forming highly experienced senior leadership team and earlier this year announcing research collaboration and license deal with Pfizer  – The financing round was co-led by Aisling Capital and HBM Healthcare Investments with participation from new investors Pfizer, ArrowMark Partners and Revelation Partners, along with all current insiders FOSTER CITY, CA – June 14, 2022 – Dren Bio, Inc. (“Dren Bio” or the “Company”) today announced the completion of their $65 million Series B financing, pushing the Company’s total capital received to date over $156 million. Following the financing, Dren Bio is well-capitalized to reach multiple key inflection points across both its drug discovery programs over the coming years.“We are truly grateful for all the support we continue to receive from such an outstanding syndicate of investors,” said Nenad Tomasevic, Ph.D., Chief Executive Officer of Dren Bio. “This financing comes at the perfect time as we prepare to initiate the first clinical trial evaluating DR-01, our lead asset, in patients with Large Granular Lymphocytic leukemia or cytotoxic lymphomas in mid-2022. In addition to advancing DR-01, the proceeds from this latest round will also enable us to further expand the development of our internal pipeline using our proprietary Targeted Myeloid Engager and Phagocytosis Platform.”The Series B financing was co-led by Aisling Capital and HBM Healthcare Investments, with participation by new marquee investors Pfizer, ArrowMark Partners and Revelation Partners. There was also significant participation in the round by Dren Bio’s existing insiders SR One, 8VC, Taiho Ventures, BVF PartneOKrs, Mission BioCapital and Alexandria Venture Investments, amongst others. In connection with the closing of the financing, the Company announced that Andrew Schiff, M.D., of Aisling Capital, and Chandra P. Leo, M.D., of HBM Partners, will join its Board of Directors.“We were thoroughly impressed by Dren Bio’s diversified R&D portfolio that encompasses two distinct therapeutic antibody programs including their attractive proprietary platform,” said Dr. Schiff, Managing Partner at Aisling Capital. “We are excited by the opportunity to support Dren Bio in progressing on their mission to deliver revolutionary therapies to patients with severe unmet needs, starting with difficult-to-treat cancers.”

Revelation Partners Investments

22 Investments

Revelation Partners has made 22 investments. Their latest investment was in Syapse as part of their Unattributed VC on July 7, 2022.

CBI Logo

Revelation Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/27/2022

Unattributed VC

Syapse

$35M

No

1

5/9/2022

Series B

Aspen Neuroscience

$147.5M

Yes

4

4/6/2022

Series C

IntelyCare

$115M

Yes

4

3/29/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

3/9/2022

Series E

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/27/2022

5/9/2022

4/6/2022

3/29/2022

3/9/2022

Round

Unattributed VC

Series B

Series C

Series B

Series E

Company

Syapse

Aspen Neuroscience

IntelyCare

Subscribe to see more

Subscribe to see more

Amount

$35M

$147.5M

$115M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

4

4

10

10

Revelation Partners Portfolio Exits

2 Portfolio Exits

Revelation Partners has 2 portfolio exits. Their latest portfolio exit was NeuroPace on April 22, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/22/2021

IPO

$99M

Public

10

3/29/2021

Acq - Pending

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/22/2021

3/29/2021

Exit

IPO

Acq - Pending

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Public

Subscribe to see more

Sources

10

10

Revelation Partners Fund History

4 Fund Histories

Revelation Partners has 4 funds, including Revelation Healthcare Fund III.

Closing Date

Fund

Fund Type

Status

Amount

Sources

3/18/2021

Revelation Healthcare Fund III

$350M

1

6/12/2018

LEERINK Revelation Healthcare Fund II LP

Subscribe to see more

Subscribe to see more

$99M

10

6/11/2015

LEERINK Revelation Healthcare Fund I

Subscribe to see more

Subscribe to see more

$99M

10

Revelation Alpine

10

Closing Date

3/18/2021

6/12/2018

6/11/2015

Fund

Revelation Healthcare Fund III

LEERINK Revelation Healthcare Fund II LP

LEERINK Revelation Healthcare Fund I

Revelation Alpine

Fund Type

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Amount

$350M

$99M

$99M

Sources

1

10

10

10

Revelation Partners Team

1 Team Member

Revelation Partners has 1 team member, including current Managing Partner, Michael Boggs.

Name

Work History

Title

Status

Michael Boggs

Saints Capital, and RBC Capital Markets

Managing Partner

Current

Name

Michael Boggs

Work History

Saints Capital, and RBC Capital Markets

Title

Managing Partner

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.